Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 48Rectal Neoplasms 42Pancreatic Neoplasms 29Esophageal Squamous Cell Carcinoma 19Adenocarcinoma Of Esophagus 15Stomach Neoplasms 14Colorectal Neoplasms 8Anus Neoplasms 8Carcinoma, Hepatocellular 7Neoplasms 6Neoplasm Metastasis 6Cholangiocarcinoma 5Locally Advanced Rectal Cancer 4Uterine Cervical Neoplasms 3Sarcoma 3Melanoma 3Anal Canal Carcinoma 3Adenocarcinoma 3Vulvar Neoplasms 2Vaginal Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Esophageal Diseases 2Endometrial Neoplasms 2Diabetes Mellitus, Insulin-Dependent, 12 2Colonic Neoplasms 2Clinical Stage I Gastric Cancer AJCC v8 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Chemoradiotherapy 2Radiation 1Paclitaxel 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Cetuximab 1Carboplatin 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Esophageal Cancer × Radiation × Gastrointestinal × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡